Inflammation significantly impacts the progression of Huntington's disease (HD) and the mutant HTT protein determines a pro-inflammatory activation of microglia. Mesenchymal stem/stromal cells (MSC) from the amniotic membrane (hAMSC), and their conditioned medium (CM-hAMSC), have been shown to possess protective effects in vitro and in vivo in animal models of immune-based disorders and of traumatic brain injury, which have been shown to be mediated by their immunomodulatory properties.
clinical disease remain incompletely understood, it has been shown that mHTT interferes with several intracellular activities including protein degradation, and mitochondrial respiration and transcription, leading to neuronal malfunction and cell death.
Recent data demonstrate the existence of inflammatory processes in HD pathophysiology. As a matter of fact, there is substantial evidence that the expression of mutant HTT protein results in a pro-inflammatory activation of microglia which influences disease onset and progression. 3 More specifically, inflammatory cytokines have been detected in the striatum of HD patients compared with that of healthy individuals 4 and also in the plasma and cerebrospinal fluid of HD patients. 3 Furthermore, pro-inflammatory (M1) microglia relevant biomarkers have been detected in the brains of HD patients, which
indicates that M1 microglia may play a crucial role in the pathogenesis of HD. 5 These findings indicate that central and peripheral inflammation may represent a critical juncture in the progression and amplification of HD pathology that, if understood, could support the development of anti-inflammatory-based treatment options.
Indeed, current anti-inflammatory therapies have been tested in animal models and in patients with HD, 6 such as XPro595, an inhibitor of TNF-α 7 and Laquinimod (NCT02215616), an immunomodulator of activated monocytes. 8 Although not belonging to the classical definition of anti-inflammatory drugs, minocycline and cannabinoids have also been tested in HD and have been shown to possess antiinflammatory properties in preclinical studies and clinical trials. [9] [10] [11] However, the protective effects of minocycline are controversial, despite the fact that minocycline has been reported to be well tolerated and safe, 10 a worsening of the disease along with detrimental effects, have been reported in animal models 12, 13 and HD patients. 14 In addition to anti-inflammatory drugs, the use of cell therapies, and more specifically of mesenchymal stem/stromal cells (MSCs) has become increasingly attractive for neurodegenerative disorders. The ability to work synergistically with the endogenous microenvironment to stimulate resident cell proliferation or neuroprotection via trophic factor secretion, enhances the regenerative potential in injured tissue. 15 Mesenchymal stem/stromal cells from bone marrow have been used in HD mouse models resulting in a decrease of the striatum atrophy and an increase differentiation of endogenous neural stem cells. 16 Furthermore, MSCs engineered to overexpress brain-derived neurotrophic factor (BDNF) were shown to improve motor activity in R6/2 mice. 17 Brain-derived neurotrophic factor plays a major role in the survival of mature neurons in the striatum, 18 and is decreased in brain tissue from HD patients. 19 Indeed, an ongoing prospective observational study is investigating genetically-engineered MSC to secrete BDNF in HD patients (PRE-CELL: Clinicaltrials.gov identifier NCT01937923), 20 and subsequently a Phase I trial will be performed to assess the safety of genetically-modified MSCs to treat HD in patients.
In the context of MSC, those derived from the amniotic membrane of human term placenta (hAMSC) have attracted much attention for several reasons. First, the use of placenta as a cell source bypasses the problem of the availability of tissue source since placenta is normally discarded as medical waste after birth, and it is easy to obtain without ethical controversy. Second, hAMSC possess strong immunomodulatory properties and transplantation of hAMSC has repeatedly shown to favour tissue repair and regeneration in rodent models of inflammatory-based diseases. 21 Similar benefits were achieved when cell-free treatments were used, such as conditioned media containing cell-secreted factors during in vitro culture.
Bioactive factors produced by amniotic cells (ie secretome) are able to act on different inflammatory mediators in vitro. More specifically, the hAMSC secretome has been shown to induce anti-proliferative effects on T cells, skew T cell polarization by enhancing T regulatory cells and reducing Th1 and Th17 populations, and inhibit the differentiation of monocyte-derived dendritic cells. 22 Of particular interest is a recent finding that hAMSC and conditioned medium from hAMSC (CM-hAMSC) induced comparable protection in in vitro and in vivo models of traumatic brain injury. 23 More specifically, they enhanced neuronal rescue, decreased pro-inflammatory M1 and promoted M2 microglia polarization, and induced neurotrophins involved in neuronal and vascular remodelling (BDNF and vascular endothelial growth factor, VEGF). In addition to BDNF, other neurotrophins such as nerve growth factor (NGF) and neurotrophin-3 (NT-3) have been reported to be expressed by amnion. 24 Furthermore, metabolomic profiling has shown that CM-hAMSC contains lysine, taurine, alpha-aminoadipic-acid and spermidine, 23 all of which have been reported to possess neuroprotective effects. [25] [26] [27] [28] [29] Conditioned medium from hAMSC has also been reported to contain antiinflammatory molecules 22 and various factors implicated in the growth, differentiation, vascularization and survival of neurons and synapses, including interleukin 10 (IL-10), transforming growth factor beta (TGF-β), 30 hepatocyte growth factor (HGF), 31 prostaglandin E2 (PGE2), 32 angiogenin 33 and leptin. 34 At present, there are few options to treat the symptoms of HD and no therapy to slow the neurodegenerative process. Here, we hypothesize that the immunomodulatory actions and the trophic factors in CM-hAMSC could have beneficial effects in a mouse model of HD, thus supporting the potential development of a cell-free therapy. The purpose of this study was to assess a novel therapeutic intervention with CM-hAMSC in symptomatic HD mice, and investigate if CM-hAMSC ameliorates the behavioural and neuropathological sequel of mutant huntingtin (mHtt).
| MATERIALS AND METHODS

| Isolation of hAMSC and preparation of CM
Human term placentae were collected at the Department of Obstetrics in the body weights of male and female mice within each group were analysed separately. The criterion for euthanasia was the point in time when mice could no longer stand after being placed on their side for 30 seconds, according to Stack and co-workers. 
| Analysis of motor coordination (rotarod)
Motor coordination and balance were estimated using a five-station mouse rotarod (Rotarod/RS LSI Letica, Biological Instruments, Varese, Italy). Four-week old mice were trained at increasing speeds up to a constant speed of 14 rpm for three consecutive trials. Subsequently, they were administered one rotarod trial twice a week from 5 to 13 weeks of age. Mice were given three trials on the rod, and their latencies to fall were measured and averaged. A maximum latency of 60 seconds was defined.
| Analysis of motor activity (open field)
Motor activity was measured in an open field consisting of a circular arena (60 cm diameter) with the floor divided into central and peripheral sectors by black lines. Mice were placed in the arena for 10 minutes during which the distance travelled was recorded by means of dedicated software (Noldus, Wageningen, the Netherlands).
| Clasping
When suspended by the tail, R6/2 mice exhibit a hind-limb clasping phenotype that indicates neurological impairment. 39 Mice were suspended by their tail for 60 seconds. The total amount of time spent
clasping was recorded twice a week and the average clasping duration per week was calculated.
| Morphological studies
Under deep anaesthesia mice were transcardially perfused with saline solution followed by 60 mL of 4% paraformaldehyde in saline solution. Brains were removed, collected and post fixed in 4% paraformaldehyde overnight. The following day, brains were cryoprotected in 10% sucrose and 20% glycerol in 0.1 mol/L phosphate buffer with sodium azide 0.02% for 48 hours at 4°C. Frozen brains were subsequently sectioned at a 40 μm-thickness using a sliding microtome.
| Analysis of striatal volume
Coronal step serial sections from rostral neostriatum through the 
| Evaluation of neuronal intranuclear inclusion
| Analysis of microglial activation
Activated microglia were detected in the striatum by immunolabelling with rat anti-mouse CD68 antibody (1:300; Immunological Figure 5A . Images were acquired using a CLSM (Zeiss LSM 700) laser-scanning confocal microscope under nonsaturating exposure conditions and using the same acquisition settings for all samples. The conditions in terms of gain and laser power were selected at levels that allowed optimal visualization of the fluorophore used as secondary antibody and standardized using sections from wild-type mice. Each image was saved at a resolution of 1024 × 1024 pixels. These settings were applied as standard for subsequent images. Using a 40× objective, Z-stacks images of striatum from coronal sections were collected using computer controlled microstepper stage of the confocal microscope. Images stacks were combined into a single two-dimensional (2D) projection image, exported in TIF file format using NIH ImageJ software and, using the adjusted threshold function, the area of CD68 positive tissue was quantified. The CD68 immunostained area was calculated as CD68
immunostained area/the total area analysed and indicated as staining percentage area.
| Western blotting
Protein lysates were obtained from the striatum by homogenization 
| Statistical analysis
The data collected were analysed to compare the effect of CMhAMSC on behavioural and neuropathological outcomes of the different treatment groups. Statistical analysis was performed using either a one-way or a two-way repeated measures ANOVA followed by HSD Tukey test. P values less than 0.05 were considered to be statistically significant.
| RESULTS
| CM-hAMSC treatment does not affect weight loss in R6/2 mice
Progressive loss of body weight is a consistent and robust feature of R6/2 mice. 36 When compared to wild-type mice treated with saline, there was a significant decline of body weight in both female and male R6/2 mice at 11 (P < 0.01), 12 (P < 0.01) and 13 (P < 0.001) weeks of age which represents the time at which R6/2 mice manifest clinical symptoms ( Figures 1A,B) . In both genders, we found no significant effect of CTRL or CM-hAMSC on body weight loss of R6/2 mice ( Figure 1A ,B).
| The onset of the clasping reflex is ameliorated in R6/2 mice treated with CM-hAMSC
The clasping reflex, an abnormal posturing of the hind limb during the tail suspension, is a typical phenotype alteration characteristic of R6/2 mice 36 that reflects the progression of brain damage. Clasping is absent in wild-type mice. In saline-treated R6/2 mice, the clasping response was evident by 9 weeks of age and then developed progressively and reached the maximal levels by 13 weeks of age, when the mice are full symptomatic (Figure 2A ). R6/2 + CTRL steadily increased their clasping behaviour starting from 11 weeks of age until 13 weeks of age, at which time there was no difference compared to R6/2 mice treated with saline. In contrast, the clasping response developed more gradually in R6/2 mice treated with CM-hAMSC. Indeed, the time spent exhibiting the clasping response was significantly less in the CM-hAMSC-treated mice compared to saline-treated R6/2 mice at 12
and 13 weeks of age (Figure 2A , P < 0.00002). Moreover, at 12 and 13 weeks of age when fully symptomatic, R6/2 mice treated with CMhAMSC showed less clasping compared to mice treated with CTRL ( Figure 2A , P < 0.00002). These data indicated that CM-hAMSC was highly effective in attenuating clasping behaviour detected in a response that reflects dystonia.
| R6/2 mice treated with CM-hAMSC show improvements in motor coordination
To further characterize the effect of CM-hAMSC treatment on behavioural phenotype, we tested motor coordination and balance by rotarod analysis. Mice were trained to maintain balance on an accelerating rotarod beginning at 5 weeks of age and then tested weekly until 13 weeks of age. Motor coordination was severely impaired in saline-treated R6/2 mice in a time-dependent manner compared to WT mice (significant effect of time: F(5.79) = 51.37; P < 0.0001).
Conditioned medium from hAMSC affected performance in a groupdependent fashion (significant group × time interaction: F (40.632) = 18.89; P < 0.0002). There was a significantly higher performance in CM-hAMSC-treated R6/2 mice than the saline-or CTRLtreated R6/2 mice at 12 and 13 weeks of age, suggesting that, the CM-hAMSC-treated R6/2 mice advanced with significantly less severity in the late stage of HD ( Figure 2B ).
| CM-hAMSC treatment ameliorates motor activity
Finally, to confirm the improvement in motor performance and to study the exploration levels, we performed the open field test.
Motor activity data collected in the open field test indicated that R6/ 2 mice showed a progressive decrease in spontaneous locomotor and exploratory activity in the arena when compared with wild-type mice ( Figure 2C ; group effect for total distance moved F (3.87) = 35.28; P < 0.0001). This significant increase to hypoactivity was equally observed in R6/2 mice treated with CTRL medium as there were no statistically significant differences between saline-or F I G U R E 1 Effects of conditioned medium from hAMSC (CM-hAMSC) on the body weights of R6/2 mice. Body weights of (A) male and (B) female wild-type (WT) mice treated with saline, and R6/2 mice treated with saline, control medium (CTRL) or CM-hAMSC. Data are presented as mean + SD. There was no significant effect of CM-hAMSC on the body weight of male and female R6/2 mice; **P < 0.01 and ***P < 0.001 vs WT + saline GIAMPÀ ET AL.
| 1585 CTRL-treated R6/2 mice ( Figure 2C ). The CM-hAMSC-treated R6/2 mice travelled a significantly greater distance than the vehicle-treated R6/2 animals in the late stage of disease (from 11 weeks up to 13 weeks of age (P < 0.00002, Figure 2C ).
For all three motor activity assessments (clasping, rotarod, open field) no differences were observed between WT mice treated with saline, CTRL medium and CM-hAMSC (data not shown).
| Improvement of neuropathological assessments of R6/2 mice after treatment with CM-hAMSC
Since CM-hAMSC-treated R6/2 mice showed greater preservation of their striatal-dependent motor coordination than saline-or CTRLtreated R6/2 mice, we next evaluated whether striatal neuropathology correlated with these behavioural results. 
| Striatal volume
Striatal atrophy in R6/2 mice was assessed by measuring striatal areas in the calbindin-stained brain sections in 13-week old mice ( Figure 3 ). Figure 3A shows representative microphotographs of coronal sections immunostained for calbindin. The area of the striatum was significantly reduced in brain sections from saline-treated R6/2 mice compared with those from saline-treated WT mice (P < 0.01; Figure 3B ). Repeated treatment with CM-hAMSC significantly inhibited the decline of striatal area in R6/2 mice (P < 0.05; Figure 3B ). Unexpectedly, the treatment with the CTRL was also able to reduce neurodegeneration in the striatum of R6/2 mice and there was no difference when compared to CM-hAMSC-treated R6/ 2 mice.
| mHtt aggregation
The and both CM-hAMSC-or CTRL-treated R6/2 (P > 0.05; Figure 4B ).
However, when we measured the area of NIIs, we found a marked reduction in mHtt size in R6/2 treated with CM-hAMSC when compared with saline-(P < 0.0001) or CTRL-treated (P < 0.0001) R6/2 mice, thus indicating that the treatment with CM-hAMSC was able to reduce the aggregation of mutant Huntingtin ( Figure 4C ).
| CM-hAMSC protects R6/2 mice against neuroinflammation
Due to the well-documented immunomodulatory properties of CMhAMSC, we asked whether the beneficial effects of conditioned medium could be associated with an anti-inflammatory effect exerted in the striatum of R6/2 mice model. Thus, we investigated the expression of CD68 (marker for activated microglia) and iNOS (pro-inflammatory, M1 marker). To evaluate microglia reactivity, we performed CD68 immunostaining in the striatum ( Figure 5A ) and quantified the surface covered by CD68 ( Figure 5B,C) . 42 Immunostaining for CD68 in saline-treated R6/ 2 mice group revealed an intense microglial reaction, where microglial cells positive for CD68 were numerous and the area of the reaction was higher compared to that observed in wild-type mice ( Figure 5C ,
Microglial reactions were significantly attenuated in R6/2 mice treated with CM-hAMSC when compared to R6/2 mice treated with either saline ( Figure 5C , P < 0.001) or CTRL (P < 0.01). These data show that the activation of microglia persists in the late stage of disease when the animals are fully symptomatic, and that treatment with CM-hAMSC is able to decrease microglia activation.
| CM-hAMSC treatment reduces iNOS levels in the striatum of R6/2 mice
We investigated inflammatory markers that could potentially be involved in the decrease of CD68 after CM-hAMSC treatment. More specifically, we evaluated the expression of the inducible isoform of nitric oxide synthase (iNOS), a well-established source of nitric oxide during inflammation of the central nervous system (CNS) and considered a functional marker of M1 phenotype microglia. 41 Evidence of F I G U R E 3 Effects of Conditioned medium from hAMSC (CMhAMSC) treatment on striatal atrophy in R6/2 mice at 13 weeks of age. A, Transmitted light microscope images showing representative calbindin-stained coronal sections of a wild-type (WT) mice treated with saline, and saline-, CTRL-or CM-hAMSC-treated R6/2 mice. Marked gross striatal atrophy (black arrows) and enlarged lateral ventricles (white arrows) are present in vehicle-treated R6/2 mice compared to wild-type mice. This atrophy is mostly absent from the sections of the R6/2 mouse treated with CTRL or CM-hAMSC. B, Quantification of differences in striatal volume in the same groups as (A). Post hoc analysis indicated that R6/2 mice treated with saline had a significantly reduced striatal volume compared to the wildtype group (*P < 0.05; **P < 0.01) increased iNOS expression has been observed in HD animal models. 43 In line with these findings, we found an elevated expression of iNOS in the striatum of saline-treated R6/2 mice when compared with wild-type mice ( Figure 5D , P < 0.001). Moreover, levels of iNOS were significantly reduced by treatment with CM-hAMSC compared to both saline-and CTRL-treated R6/2 mice ( Figure 5D , P < 0.01).
| CM-hAMSC treatment does not alter BDNF expression in the striatum of R6/2 mice
Brain-derived neurotrophic factor is one of the principal mediators whose deficiency contributes to the pathology caused by mutant
Huntingtin in mice and in HD patients. 18 Thus, we investigated the Although it is widely reported that BDNF, an important neuroprotective factor, is reduced in HD patients and in HD animal models 19, 49 the beneficial effect of CM-hAMSC observed in this study could be BDNF-independent. Indeed, we did not observe any increase of BDNF levels in the striatum of R6/2 mice treated with CM-hAMSC.
Our data are in line with recent evidence showing that improvement of HD symptoms in the R6/1 mouse model did not correlate with an increase in BDNF. 50 In addition to a reduction of BDNF, a hallmark of HD that exacerbates neurodegeneration and neurological symptoms is the pro-inflammatory activation of microglia induced by mHtt aggregates. 51 In this regard, our findings indicate that CM-hAMSC-treatment reduced the aggregation of mHtt and reduced the area of activated microglia in the striatum of R6/2 mice.
Importantly, we observed a reduction of inducible nitric oxide synthase (iNOS) levels in the striata of CM-hAMSC-treated mice.
The enzyme iNOS is commonly up-regulated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, 52 and HD. 43, 53, 54 Inducible nitric oxide synthase activation has been shown to contribute to oxidative neuronal death in R6/2 transgenic HD mice, 54 and it is primarily found in microglia with an M1 phenotype. 41 In line with our observations, other studies have shown that a decrease of iNOS delays disease progression in preclinical models of HD. 53, 55, 56 The reduction of iNOS expression and microglia activation could be explained by the presence of anti-inflammatory 62 In this study, the authors show that repeated intraperitoneal administration of extract from adipose tissue MSC improved performance in the rotarod test, and ameliorated striatal atrophy and mHtt aggregation in the striatum. 62 These results are similar to our observations herein, and in addition, we show the beneficial effect of CM-hAMSC on microglia activation. While the mechanism underlying the beneficial properties of CM-hAMSC remains unclear and deserves further investigation, the peripheral administration of CM-hAMSC, and its immunomodulatory properties, suggest that the effect of CM-hAMSC on the peripheral immune system could indirectly influence the CNS. In support of this hypothesis evidence has shown the existence of a bidirectional communication between the injured brain and the peripheral immune system. 63, 64 In conclusion, in this study we show for the first time that peripheral administration of a cell-free treatment from amniotic MSC is sufficient to induce a protective effect in the CNS of an animal model for HD.
Even though the immunomodulatory properties of CM-hAMSC, and the bioactive factors implicated in these effects, remain to be clarified, this study reinforces the evidence of the therapeutic properties of hAMSC derivatives in diseases with aberrant inflammatory processes, and in particular opens a novel scenario for a cell-free therapeutic strategy in HD.
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